Advertisement

European Spine Journal

, Volume 28, Issue 6, pp 1480–1490 | Cite as

Prognostic significance of pretreatment plasma D-dimer levels in patients with spinal chordoma: a retrospective cohort study

  • Bo Li
  • Hao Zhang
  • Pingting Zhou
  • Jiaxiang Yang
  • Haifeng Wei
  • Xinghai Yang
  • Cheng YangEmail author
  • Zhipeng WuEmail author
  • Jianru XiaoEmail author
Original Article

Abstract

Purpose

Plasma D-dimer levels, a marker of hypercoagulation, have not only been used as an indicator for cascaded reaction in the coagulation process but are also reported to be an underlying biomarker in several types of cancers. This retrospective cohort study was designed to evaluate the prognostic value of preoperative plasma D-dimer level in patients with spinal chordoma.

Methods

We enrolled 224 patients who underwent surgery for spinal chordoma between 2002 and 2015 at Changzheng Orthopedic Oncology Center. Preoperative clinical parameters were recorded and evaluated by univariate and multivariate Cox regression models. The correlation between preoperative plasma D-dimer levels and survival was assessed using the Kaplan–Meier method.

Results

The optimal cutoff value of pretreatment D-dimer was 840 μg/L determined by X-tile. DFS (disease-free survival) was 64.7% and OS (overall survival) was 75% in the cohort. Multivariate Cox regression model identified D-dimer level as an independent prognostic factor of DFS and OS, as well as treatment history, preoperative Karnofsky Performance Scale, preoperative Frankel score, pathology classification and adjuvant radiotherapy (p < 0.05). In addition, D-dimer level may also be an effective supplement for defining tumor Enneking staging (p < 0.05).

Conclusions

Higher pretreatment plasma D-dimer level was associated with a poor prognosis in chordoma and could be used as an independent prognostic factor for the survival of the patients with spinal chordoma. With supplementation of D-dimer level, Enneking stage may be more able to accurate stratify individualized risk and determine clinical management.

Graphical abstract

These slides can be retrieved under Electronic Supplementary Material.

Keywords

Spinal chordoma D-dimer Surgery Disease-free survival Overall survival 

Notes

Funding

This study is supported by the National Natural Science Foundation of China (Grant No. 81702659).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

586_2018_5872_MOESM1_ESM.pptx (16 mb)
Supplementary material 1 (PPTX 16357 kb)
586_2018_5872_MOESM2_ESM.tif (44.9 mb)
Supplementary Figure. A typical case treated in our center. A male patient, 69 years old, suffering urination disorder and sphincter disturbances for 6 months had an en bloc surgery in our center and was diagnosed with chordoma by pathologists. (A) Plain radiographs of the patients; the typical bone erosion and tumor’s profiles can be observed. (B) Soft tissue invasion is obviously demonstrated on the magnetic resonance imaging (MRI). (C) Bone erosion was revealed by computed tomography (CT). (D) Intraoperative photograph of en bloc resection surgery; the tumor was removed integrally. (E) Comparison of the preoperational 3D-printing model and the tumor. (F) The post-surgery X-ray imaging shows that the sacrum was resected and the internal fixation was solid and successful. (TIFF 45944 kb)

References

  1. 1.
    Healey JH, Lane JM (1989) Chordoma: a critical review of diagnosis and treatment. Orthop Clin North Am 20:417–426Google Scholar
  2. 2.
    Dorfman HD, Czerniak B (1995) Bone cancers. Cancer 75:203–210CrossRefGoogle Scholar
  3. 3.
    Yang Y, Niu X, Li Y, Liu W, Xu H (2017) Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute. Eur Spine J 26:1910–1916.  https://doi.org/10.1007/s00586-016-4906-5 CrossRefGoogle Scholar
  4. 4.
    Ailon T, Torabi R, Fisher CG, Rhines LD, Clarke MJ, Bettegowda C, Boriani S, Yamada YJ, Kawahara N, Varga PP, Shin JH, Saghal A, Gokaslan ZL (2016) Management of locally recurrent chordoma of the mobile spine and sacrum: a systematic review. Spine (Phila Pa 1976) 41(Suppl 20):S193–S198.  https://doi.org/10.1097/brs.0000000000001812 CrossRefGoogle Scholar
  5. 5.
    Horten BC, Montague SR (1976) In vitro characteristics of a sacrococcygeal chordoma maintained in tissue and organ culture systems. Acta Neuropathol 35:13–25CrossRefGoogle Scholar
  6. 6.
    Salisbury JR, Isaacson PG (1986) Distinguishing chordoma from chondrosarcoma by immunohistochemical techniques. J Pathol 148:251–252.  https://doi.org/10.1002/path.1711480309 CrossRefGoogle Scholar
  7. 7.
    Tai PT, Craighead P, Liem SK, Jo BH, Stitt L, Tonita J (2000) Management issues in chordoma: a case series. Clin Oncol (R Coll Radiol) 12:80–86Google Scholar
  8. 8.
    Sun X, Hornicek F, Schwab JH (2015) Chordoma: an update on the pathophysiology and molecular mechanisms. Curr Rev Musculoskelet Med 8:344–352.  https://doi.org/10.1007/s12178-015-9311-x CrossRefGoogle Scholar
  9. 9.
    Endo K, Yamashita H, Nagashima H, Teshima R (2014) Sacral chordoma in an adult showing an aggressive clinical course: a case report. Oncol Lett 7:1443–1446.  https://doi.org/10.3892/ol.2014.1892 CrossRefGoogle Scholar
  10. 10.
    Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ (2012) Chordoma: current concepts, management, and future directions. Lancet Oncol 13:e69–e76.  https://doi.org/10.1016/S1470-2045(11)70337-0 CrossRefGoogle Scholar
  11. 11.
    Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH (2007) Chordoma: the nonsarcoma primary bone tumor. Oncologist 12:1344–1350.  https://doi.org/10.1634/theoncologist.12-11-1344 CrossRefGoogle Scholar
  12. 12.
    Pennicooke B, Laufer I, Sahgal A, Varga PP, Gokaslan ZL, Bilsky MH, Yamada YJ (2016) Safety and local control of radiation therapy for chordoma of the spine and sacrum: a systematic review. Spine (Phila Pa 1976) 41(Suppl 20):S186–S192.  https://doi.org/10.1097/brs.0000000000001831 CrossRefGoogle Scholar
  13. 13.
    Safari M, Khoshnevisan A (2014) An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma. World J Stem Cells 6:53–64.  https://doi.org/10.4252/wjsc.v6.i1.53 CrossRefGoogle Scholar
  14. 14.
    Yang H, Zhu L, Ebraheim NA, Liu J, Shapiro A, Castillo S, Liu X, Tang T (2010) Surgical treatment of sacral chordomas combined with transcatheter arterial embolization. J Spinal Disord Technol 23:47–52.  https://doi.org/10.1097/BSD.0b013e31819630ec CrossRefGoogle Scholar
  15. 15.
    Meng T, Yin H, Li B, Li Z, Xu W, Zhou W, Cheng M, Wang J, Zhou L, Yang X, Liu T, Yan W, Song D, Xiao J (2015) Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center. Neuro-oncology 17:725–732.  https://doi.org/10.1093/neuonc/nou331 CrossRefGoogle Scholar
  16. 16.
    Li W, Tang Y, Song Y, Chen SH, Sisliyan N, Ni M, Zhang H, Zeng Q, Hou B, Xie X, Chang D (2018) Prognostic role of pretreatment plasma d-dimer in patients with solid tumors: a systematic review and meta-analysis. Cell Physiol Biochem 45:1663–1676.  https://doi.org/10.1159/000487734 CrossRefGoogle Scholar
  17. 17.
    Phillips RS, Wade R, Lehrnbecher T, Stewart LA, Sutton AJ (2012) Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med 10:6.  https://doi.org/10.1186/1741-7015-10-6 CrossRefGoogle Scholar
  18. 18.
    Zhang J, Zhang HY, Li J, Shao XY, Zhang CX (2017) The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Oncotarget 8:68837–68846.  https://doi.org/10.18632/oncotarget.18575 Google Scholar
  19. 19.
    Hobusch GM, Bodner F, Walzer S, Marculescu R, Funovics PT, Sulzbacher I, Windhager R, Panotopoulos J (2016) C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum—a single center pilot study. World J Surg Oncol 14:111.  https://doi.org/10.1186/s12957-016-0875-8 CrossRefGoogle Scholar
  20. 20.
    Rowbotham BJ, Carroll P, Whitaker AN, Bunce IH, Cobcroft RG, Elms MJ, Masci PP, Bundesen PG, Rylatt DB, Webber AJ (1987) Measurement of crosslinked fibrin derivatives—use in the diagnosis of venous thrombosis. Thromb Haemost 57:59–61CrossRefGoogle Scholar
  21. 21.
    Sechi LA, Zingaro L, Catena C, Casaccio D, De Marchi S (2000) Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension 36:978–985CrossRefGoogle Scholar
  22. 22.
    Yang X, Ren H, Sun Y, Zhang L, Yang X, Li H, Shao Y, Fu J (2017) The prognostic value of D-dimer levels in endometrial cancer patients treated with intensity-modulated radiation therapy. Oncotarget 8:25279–25288.  https://doi.org/10.18632/oncotarget.15805 Google Scholar
  23. 23.
    Motavaf E, Sunesen KG, Stender MT, Thorlacius-Ussing O (2014) Prognostic value of preoperative D-dimer and carcinoembryonic antigen levels in patients undergoing intended curative resection for colorectal cancer: a prospective cohort study. Int J Colorectal Dis 29:1427–1432.  https://doi.org/10.1007/s00384-014-2000-1 CrossRefGoogle Scholar
  24. 24.
    Kilic M, Yoldas O, Keskek M, Ertan T, Tez M, Gocmen E, Koc M (2008) Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis 10:238–241.  https://doi.org/10.1111/j.1463-1318.2007.01374.x CrossRefGoogle Scholar
  25. 25.
    Ge LP, Li J, Bao QL, Chen P, Jiang Q, Zhu LR (2015) Prognostic and predictive value of plasma D-dimer in advanced non-small cell lung cancer patients undergoing first-line chemotherapy. Clin Transl Oncol 17:57–64.  https://doi.org/10.1007/s12094-014-1198-2 CrossRefGoogle Scholar
  26. 26.
    Chen Y, Yu H, Wu C, Li J, Jiao S, Hu Y, Tao H, Wu B, Li A (2016) Prognostic value of plasma D-dimer levels in patients with small-cell lung cancer. Biomed Pharmacother 81:210–217.  https://doi.org/10.1016/j.biopha.2016.02.030 CrossRefGoogle Scholar
  27. 27.
    Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252–7259.  https://doi.org/10.1158/1078-0432.CCR-04-0713 CrossRefGoogle Scholar
  28. 28.
    Dreghorn CR, Newman RJ, Hardy GJ, Dickson RA (1990) Primary tumors of the axial skeleton. Experience of the Leeds Regional Bone Tumor Registry. Spine (Phila Pa 1976) 15:137–140CrossRefGoogle Scholar
  29. 29.
    Lew AS, Berberian L, Cercek B, Lee S, Shah PK, Ganz W (1986) Elevated serum D dimer: a degradation product of cross-linked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction. J Am Coll Cardiol 7:1320–1324CrossRefGoogle Scholar
  30. 30.
    Eisenberg PR, Jaffe AS, Stump DC, Collen D, Bovill EG (1990) Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. Circulation 82:1159–1168CrossRefGoogle Scholar
  31. 31.
    Caine GJ, Stonelake PS, Lip GY, Kehoe ST (2002) The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 4:465–473.  https://doi.org/10.1038/sj.neo.7900263 CrossRefGoogle Scholar
  32. 32.
    Robson SC, Shephard EG, Kirsch RE (1994) Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 86:322–326CrossRefGoogle Scholar
  33. 33.
    Simpson-Haidaris PJ, Rybarczyk B (2001) Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann NY Acad Sci 936:406–425CrossRefGoogle Scholar
  34. 34.
    Rickles FR, Edwards RL (1983) Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 62:14–31Google Scholar
  35. 35.
    Strickland BA, McCutcheon IE, Chakrabarti I, Rhines LD, Weinberg JS (2018) The surgical treatment of metastatic spine tumors within the intramedullary compartment. J Neurosurg Spine 28:79–87.  https://doi.org/10.3171/2017.5.SPINE161161 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Orthopedic Oncology, Changzheng HospitalSecond Military Medical UniversityShanghaiChina
  2. 2.Department of Radiation Oncology, Shanghai Ninth People’s HospitalShanghai Jiaotong University School of MedicineShanghaiChina
  3. 3.Anhui University of Chinese MedicineHefeiChina

Personalised recommendations